Clinical Trial Update: Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder [Phase 4]

View source ↗

Summary

A Phase 4 study examines the efficacy, safety, and tolerability of darifenacin in patients over 65 with overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Darifenacin (darifenacin)

Snippet

Sponsor: Novartis | Conditions: Overactive Bladder | Phase 4 | Status: COMPLETED